

# Drugs and Devices Division

## Drug Submission Status

Report for December 2019

## Complete Streamlined Multiple-Source

## Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp Dutasteride	Avodart	dutasteride	0.5mg	capsule	02484870
Jamp Pharma Corporation	Jamp Rivastigmine	Exelon	rivastigmine hydrogen tartrate	1.5mg	capsule	02485362
Jamp Pharma Corporation	Jamp Rivastigmine	Exelon	rivastigmine hydrogen tartrate rivastigmine hydrogen tartrate	3mg	capsule	02485370
Jamp Pharma Corporation	Jamp Rivastigmine	Exelon	rivastigmine hydrogen tartrate	4.5mg	capsule	02485389
Jamp Pharma Corporation	Jamp Rivastigmine	Exelon	rivastigmine hydrogen tartrate	6mg	capsule	02485397
Laboratoire Riva Inc.	Riva Leucovorin	Leucovorin Calcium	leucovorin calcium	5mg	tablet	02493357
Mint Pharmaceuticals Inc.	Mint-Lacosamide	Vimpat	lacosamide	50mg	FC tablet	02490544

Mint Pharmaceuticals Inc.	Mint-Lacosamide	Vimpat	lacosamide	100mg	FC tablet	02490552
Mint Pharmaceuticals Inc.	Mint-Lacosamide	Vimpat	lacosamide	150mg	FC tablet	02490560
Mint Pharmaceuticals Inc.	Mint-Lacosamide	Vimpat	lacosamide	200mg	FC tablet	02490579